The most recent trading session ended with Boston Scientific (BSX) standing at $91.29, reflecting a +0.66% shift from the previouse trading day's closing. The stock exceeded the S&P 500, which registered a gain of 0.55% for the day. Elsewhere, the Dow lost 0.06%, while the tech-heavy Nasdaq added 1.24%.Analysts and investors alike will be keeping a close eye on the performance of Boston Scientific in its upcoming earnings disclosure. The company's earnings report is set to go public on February 5, 2025. On ...

Market Performance - US stock markets experienced a significant rally in 2024, with the S&P 500 rising 23.3% following a 24.2% increase in 2023, marking a 53% gain over two years, the best since 1997-98 [1] - The Dow and Nasdaq Composite rose 12.9% and 28.6% respectively in 2024, with the S&P 500 hitting 57 all-time highs [1] Sector Performance - The 2023 rally was led by the technology sector, particularly AI-focused stocks, while the 2024 rally saw broader participation from financials, industrials, utilities, and consumer discretionary sectors [2] Investment Opportunities - Non-tech stocks that outperformed major indexes in 2024 are recommended for investment, with five highlighted stocks: Chipotle Mexican Grill, Interactive Brokers Group, KKR & Co, Fiserv, and Boston Scientific [3][4] Chipotle Mexican Grill (CMG) - CMG benefits from service digitization, new menu offerings, and restaurant openings, with 86 new restaurants opened in Q3 2024, 73 featuring Chipotlanes [5] - CMG expects 80% of new openings to include Chipotlanes, with future sales growth supported by innovations like the Augmented Make line [6] - CMG has expected revenue and earnings growth rates of 12.8% and 17.9% for 2025, with a 12.5% average price target increase from $59.89 [7] Interactive Brokers Group (IBKR) - IBKR's revenue growth is supported by proprietary software development, lower compensation expenses, and expansion in emerging markets [8] - Total net revenues are projected to grow at a CAGR of 7.6% by 2026, with sustainable capital distributions due to a solid liquidity position [9] - IBKR has expected revenue and earnings growth rates of 2.1% and 3.6% for 2025, with an 11% average price target increase from $182.50 [10] KKR & Co (KKR) - KKR benefits from growth in assets under management (AUM) and record transaction fees, with new capabilities in infrastructure, real estate, and growth investing aiding revenue growth [12] - KKR has expected revenue and earnings growth rates of 18.6% and 30% for 2025, with a 13.1% average price target increase from $149.19 [13] Fiserv (FI) - FI's growth is driven by Clover's strong performance and strategic buyouts, with a business model featuring recurring revenues and high incremental margins [15] - FI has expected revenue and earnings growth rates of 8.8% and 16.4% for 2025, with an 11.3% average price target increase from $205.98 [16] Boston Scientific (BSX) - BSX sees strength in MedSurg and Structural Heart lines, with strong demand for WATCHMAN FLX and FLX Pro, and contributions from accretive acquisitions [18] - The Pain and Brain franchises and Electrophysiology arm are expected to gain traction in 2024, with 2025 revenue and earnings growth rates of 12.9% and 12.7% [19][20]

Industry Overview - The healthcare sector is facing persistent inflationary challenges, leading to increased healthcare costs that adversely affect performance [1][14] - Health insurers are responding by designing affordable health plans and expanding into underserved U.S. communities, which supports membership growth and increases premiums [2] - The aging U.S. population is expected to sustain robust demand for Medicare plans in 2025 [2] - There is a growing need for specialized rehabilitative care, driving revenue growth for inpatient rehabilitation services and behavioral health facilities [3] - The medical device industry is encountering significant challenges due to regulatory hurdles, supply-chain disruptions, and geopolitical tensions, which have been exacerbated by inflation [4] - Healthcare companies are heavily investing in telehealth services, which are expected to generate consistent revenue streams in the long term despite initial costs [5] Company Highlights - Doximity, Inc. is leveraging strategic acquisitions and AI-powered solutions to enhance service offerings, positioning itself as a preferred partner for healthcare organizations [7] - Boston Scientific Corporation is benefiting from international expansion and innovative technologies, with strong market share gains and strategic acquisitions bolstering its position [8] - LeMaitre Vascular is capitalizing on the demand for vascular medical devices driven by an aging population and chronic diseases, supported by strategic acquisitions and R&D investments [9] - Globus Medical is expanding its market share in musculoskeletal solutions through innovative products and a merger with NuVasive, positioning itself for continued success [10] Financial Performance - Doximity's fiscal 2025 earnings estimate is $1.14 per share, indicating a 20% year-over-year growth, with shares surging 107.5% year to date [18] - Boston Scientific's 2024 earnings estimate is $2.46 per share, reflecting a 20% year-over-year improvement, with shares gaining 55.4% year to date [20] - LeMaitre Vascular's 2024 earnings estimate is $1.94 per share, indicating 43.7% year-over-year growth, with shares increasing by 61% year to date [22] - Globus Medical's 2024 earnings estimate is $2.97 per share, showing a 28% year-over-year improvement, with shares gaining 55.9% year to date [24]

The latest trading session saw Boston Scientific (BSX) ending at $89.86, denoting a +1.02% adjustment from its last day's close. This move outpaced the S&P 500's daily gain of 0.73%. At the same time, the Dow added 0.16%, and the tech-heavy Nasdaq gained 0.98%.Heading into today, shares of the medical device manufacturer had lost 1.17% over the past month, outpacing the Medical sector's loss of 3.8% and lagging the S&P 500's gain of 0.34% in that time.Investors will be eagerly watching for the performance o ...

Boston Scientific (BSX) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting stock prices -- has triggered this rating change.The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked by the system.Indi ...

When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?Let's take a look at what these Wall Street heavyweights have to say about Boston Scientific (BSX) before we discuss the reliability of brokerage recommendations and how to use them to your advantage.Boston Scientific currently has an average brokerage re ...

Boston Scientific (BSX) has been gaining from new product launches and accretive acquisitions. Yet, unfavorable currency movement and macroeconomic concerns are major dampeners. The stock carries a Zacks Rank #3 (Hold) currently.Factors Driving BSX SharesWe are particularly impressed by Boston Scientific’s recent acquisitions that have added numerous products (though many are under development) with immense potential. This, in turn, should help boost the top line in the long term.The company’s recently-comp ...

NEW YORK, Dec. 11, 2024 /PRNewswire/ -- Today's Marketplace (TMP) is proud to announce a featured interview with Boston Scientific (NYSE: BSX) Global Chief Medical Officer, Kenneth Stein, MD, and Scott Shipman, MD, MPH, Executive Director for the Institute for Population Health. The doctors joined host Jane King to discuss health inequities and Boston Scientific's work to improve access to care for underserved populations. "[We need] to address the factors that impede health equity." Post this Close the Ga ...

Boston Scientific (BSX) is gaining traction in the international markets. New regulatory approvals and accretive acquisitions bode well for long-term growth. Yet, unfavorable currency movement and macroeconomic concerns are major dampeners. The stock carries a Zacks Rank #3 (Hold).Factors Driving BSX SharesBoston Scientific successfully continues with its expansion of operations across different geographies outside the United States. In Europe, the Middle East and Africa (EMEA), Boston Scientific is success ...

Boston Scientific Corporation (BSX) has entered into a definitive agreement to acquire Intera Oncology Inc., a Boston-based life science company. The acquisition expands the company’s interventional oncology offerings with the Intera 3000 Hepatic Artery Infusion Pump and floxuridine — a chemotherapy drug — both of which are approved by the FDA.The transaction is expected to close in the first half of 2025, subject to closing conditions. Boston Scientific expects the deal to have an immaterial impact on adju ...